Is LTX-315 safe?
Phase 1 safety in 39 patients
CAnimal and cell studiesIn clinical trialsas of 2026-10-27
In the phase 1 trial, the main adverse events were local pain and inflammation at the injection site. Short-lived reactions in the body (flushing, low blood pressure, fever) followed soon after injection. These fit the release of cell contents and histamine. The most common grade 3 events were hypersensitivity or anaphylaxis, in 4 of 39 patients (10%). 1
The published literature covers only 39 treated patients. So the full side-effect profile is unknown. Anything sold online as LTX-315 for self-injection has no clinical basis. 1
More on LTX-315
Citations
- Spicer 2021, Clin Cancer Res: Phase 1 study of intratumoral LTX-315 in advanced solid tumors pubmed.ncbi.nlm.nih.gov
- Verrica Pharmaceuticals 2021: FDA acceptance of IND application for LTX-315 in basal cell carcinoma verrica.com
- ClinicalTrials.gov: NCT05188729, VP-315 phase 2 trial in basal cell carcinoma clinicaltrials.gov
Reference information only, not medical advice. Drawn from the LTX-315 article, fact-checked against the cited sources. No dosing anywhere on this site.